Is there a role for further HER2 directed therapies after progression on fam-trastuzumab deruxtecan after a sustained initial response in patients with metastatic HER2+ colorectal cancer?

Great question, but no data (yet).

The Destiny-CRC 01 study enrolled 16 patients (out of 86, 18.6%) who had previous anti-HER2 agents. All these 16 patients were in Cohort A which is HER3 IHC 3+ or IHC2+/ISH+ (total of 53 patients). In the subgroup analysis, median progression-free survival was simil...